Accession Number: | 0001562180-21-004949 |
Date: | 2021-07-13 |
Issuer: | G1 THERAPEUTICS, INC. (GTHX) |
Original Submission Date: |
VELLECA MARK A.
700 PARK OFFICES DRIVE, SUITE 200
RESEARCH TRIANGLE PARK, NC 27709
Title of Security | Transaction Date | 2a. Deemed Execution Date | Transaction Code | Shares | Acquired or Disposed | Price per share | 5. Amount of Securities Beneficially Owned Following Reported Transaction | 6. Ownership Form Direct or Indirect | Nature of Indirect Ownership |
---|---|---|---|---|---|---|---|---|---|
COMMON STOCK | 2021-07-13 | M | 10,000 | a | $0.39 | 71,000 | direct | ||
COMMON STOCK | 2021-07-13 | S | 10,000 | d | $19.45 | 61,000 | direct | ||
COMMON STOCK | 2021-07-14 | M | 10,000 | a | $0.39 | 71,000 | direct | ||
COMMON STOCK | 2021-07-14 | S | 10,000 | d | $19.08 | 61,000 | direct | ||
COMMON STOCK | 2021-07-15 | M | 10,000 | a | $0.39 | 71,000 | direct | ||
COMMON STOCK | 2021-07-15 | S | 10,000 | d | $18.49 | 61,000 | direct |
Title of Derivative Security | Conversion or Exercise Price of Derivative Security | Transaction Date | Deemed Execution Date | Transaction Code | Number of Derivative Securities Acquired (A) or Disposed of (D) | Date Exercisable | Expiration Date | Title and Amount of Securities Underlying Derivative Security | Price of Derivative Security | Number of derivative Securities Beneficially Owned Following Reported Transaction(s) | Ownership Form: Direct (D) or Indirect (I) | Nature of Indirect Beneficial Ownership |
---|---|---|---|---|---|---|---|---|---|---|---|---|
STOCK OPTIONS (RIGHT TO BUY) | 0.39 | 2021-07-13 | deemed execution date | M | 10,000 (d) | 2024-05-09 | common stock 10,000 | $0.39 | 247,286 | direct | ||
STOCK OPTIONS (RIGHT TO BUY) | 0.39 | 2021-07-14 | deemed execution date | M | 10,000 (d) | 2024-05-09 | common stock 10,000 | $0.39 | 237,286 | direct | ||
STOCK OPTIONS (RIGHT TO BUY) | 0.39 | 2021-07-15 | deemed execution date | M | 10,000 (d) | 2024-05-09 | common stock 10,000 | $0.39 | 227,286 | direct |
ID | footnote |
---|---|
f1 | this sale was effected pursuant to a rule 10b5-1 trading plan. |
f2 | the price represents the weighted average price with a low of $19.25 and a high of $19.85. the reporting person undertakes to provide g1 therapeutics, inc., any security holder of g1 therapeutics, inc., or the staff of the securities and exchange commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote 2 to this form 4. |
f3 | the price represents the weighted average price with a low of $18.90 and a high of $19.22. the reporting person undertakes to provide g1 therapeutics, inc., any security holder of g1 therapeutics, inc., or the staff of the securities and exchange commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote 3 to this form 4. |
f4 | the price represents the weighted average price with a low of $18.29 and a high of $18.64. the reporting person undertakes to provide g1 therapeutics, inc., any security holder of g1 therapeutics, inc., or the staff of the securities and exchange commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote 4 to this form 4. |
f5 | all shares underlying this option have vested. |